• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Manufacturing
    • Packaging
    • Development
    • Compliance
    • Top 25
    • Directory
    • Microsites
    • Events
    • More
  • Magazine
  • News
  • Manufacturing
  • Packaging
  • Development
  • Compliance
  • Top 25
  • Directory
  • Microsites
  • Events
  • Current / Back Issue
    Features
    Editorial
    Columns
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Subscribe Now
    Advertise Now
    Top Features
    Bye-Bye China?

    Decentralized Trials Fuel AI Revolution in Clinical Research

    Self-Medication: Flexibility for Patients and Drug Manufacturers

    The Single-Use Mixing Landscape: Evaluating Your Options

    DCAT President Talks COVID-19, Drug Manufacturing and Innovation
    Breaking News
    Online Exclusives
    Industry News
    Collaborations & Alliances
    Promotions & Moves
    Trials & Filings
    Financial Reports
    Bio News & Views
    Custom Sourcing News
    Packaging & Tracking
    CRO News
    Live From Shows
    Top News
    WDSrx Expands Warehouse Network

    Piramal Inks Clinical Supply Deal with Theratechnologies

    Recipharm Signs Manufacturing Deal with Enzymatica

    CDMO Northway Biotech Expands in U.S.

    Global Biosciences Co. Selects ValGenesis VLMS
    APIs
    Aseptic Processing
    Cleaning Validation
    Clinical Trial Materials
    Cytotoxics and High Potency Manufacturing
    Equipment
    Excipients
    Extractables and Leachables
    Facilities
    Fill/Finish
    Lyophilization
    Parenterals
    Process Development
    Process Validation
    Risk Management
    Scale-up/ Technology Transfer
    Solid Dosage/ Creams/ Ointments

    WDSrx Expands Warehouse Network

    Piramal Inks Clinical Supply Deal with Theratechnologies

    Recipharm Signs Manufacturing Deal with Enzymatica

    CDMO Northway Biotech Expands in U.S.

    Lonza to Exit Pharma Softgels and Liquid-Filled Hard Capsules
    Capsules
    Cold Chain Management
    Injectables
    Logistics
    Serialization
    Solid Dosage / Semi-solids
    Supply Chain
    Vials

    WDSrx Expands Warehouse Network

    Catalent Acquires Acorda’s INBRIJA Manufacturing Operations

    Varcode, PL Developments Form Strategic ‘Smart Tag’ Pact

    COVID-19 Vaccine Distribution: The Air Cargo Industry’s Greatest Challenge

    Thermo Fisher Expands Clinical Supply Services in Europe
    Analytical Services
    Bioanalytical Services
    Bioassay Developement
    Biologics, Proteins, Vaccines
    Biosimilars
    Chemistry
    Clinical Trials
    Drug Delivery
    Drug Development
    Drug Discovery
    Formulation Development
    Information Technology
    Laboratory Testing
    Methods Development
    Microbiology
    Preclinical Outsourcing
    R&D
    Toxicology

    Improving Product Profitability

    CDMO Northway Biotech Expands in U.S.

    Global Biosciences Co. Selects ValGenesis VLMS

    Nexelis Acquires GSK Vax Lab in Marburg

    The Future of Clinical Trials Series: Part I
    Filtration & Purification
    GMPs/GCPs
    Inspections
    QA/QC
    Regulatory Affairs
    Validation

    Global Biosciences Co. Selects ValGenesis VLMS

    Gene Therapy Co. Selects ValGenesis' SaaS Platform

    The Year of COVID: How FDA Coped with a Worldwide Pandemic in 2020 and What to Expect in 2021

    Samsung Biologics Adopts Veeva Vault QMS to Unify Quality Management

    CDMO Cognate BioServices Teams Up with L7 Informatics
    Companies
    Categories
    Corporate Capabilities
    Add New Company
    Contract Service Directory Companies
    PCI Pharma Services

    Reed-Lane

    Flow Sciences

    Adare Pharma Solutions

    Cytovance Biologics
    Companies
    News Releases
    Posters
    Brochures
    Services
    Videos
    Case Study
    White Papers
    Jobs
    Contract Service Directory Companies
    Baxter BioPharma Solutions

    Alcami

    Syngene

    Reed-Lane

    Aphena Pharma Solutions
    Webinars
    Live From Shows
    • Magazine
      • Current / Back Issue
      • Features
      • Editorial
      • Columns
      • Editorial Guidelines
      • Subscribe Now
      • Advertise Now
      • Enewsletter Archive
      • Digital Edition
    • Directory
      • Companies
      • Categories
      • Corporate Capabilities
      • Add Your Company
    • Manufacturing
      • APIs
      • Aseptic Processing
      • Cleaning Validation
      • Clinical Trial Materials
      • Cytotoxics and High Potency Manufacturing
      • Equipment
      • Excipients
      • Extractables and Leachables
      • Facilities
      • Fill/Finish
      • Lyophilization
      • Parenterals
      • Process Development
      • Process Validation
      • Risk Management
      • Scale-up/ Technology Transfer
      • Solid Dosage/ Creams/ Ointments
      • cGMP Manufacture
    • Packaging
      • Capsules
      • Cold Chain Management
      • Injectables
      • Logistics
      • Serialization
      • Solid Dosage / Semi-solids
      • Supply Chain
      • Vials
    • Development
      • Analytical Services
      • Bioanalytical Services
      • Bioassay Developement
      • Biologics, Proteins, Vaccines
      • Biosimilars
      • Chemistry
      • Clinical Trials
      • Drug Delivery
      • Drug Development
      • Drug Discovery
      • Formulation Development
      • Information Technology
      • Laboratory Testing
      • Methods Development
      • Microbiology
      • Preclinical Outsourcing
      • R&D
      • Toxicology
    • Compliance
      • Filtration & Purification
      • GMPs/GCPs
      • Inspections
      • QA/QC
      • Regulatory Affairs
      • Validation
    • Top 25 Pharma & BioPharma
    • Contract Pharma Direct
    • Breaking News
    • Online Exclusives
    • Slideshows
    • Experts Opinions
    • Surveys
      • Outsourcing Survey
      • Salary Survey
    • Glossary
    • Videos
    • Podcasts
    • White Papers
    • Infographics
    • Contract Pharma Conference
      • Contract Pharma Conference
      • Speakers
      • Exhibitors
      • Conference Sessions
    • Supplier Microsite
      • Companies
      • News Releases
      • Posters
      • Brochures
      • Services
      • Videos
      • Case Study
      • White Papers
    • eBook
    • Webinars
    • Events
      • Industry Events
      • Live from Show Events
      • Webinars
    • Classifieds / Job Bank
      • Classifieds
      • Job Bank
    • About Us
      • About Us
      • Contact Us
      • Advertise With Us
      • Privacy Policy
      • Terms of Use
    Features

    Biopharmaceutical Contract Manufacturing Market

    The market continues to grow, projected to exceed $4 billion in 2017

    Biopharmaceutical Contract Manufacturing Market
    Biopharmaceutical Contract Manufacturing Market
    Biopharmaceutical Contract Manufacturing Market
    Related CONTENT
    • Vetio Animal Health
    • Boehringer Inaugurates Biopharma Mfg. Facility in China
    • Trends in New Technologies & Budgets
    • Heading to BIO 2017!
    • Dr. Reddy’s Expands Biomanufacturing Capabilities
    William Downey, President, HighTech Business Decisions06.06.17
    The growth in outsourced commercial and development biopharmaceutical programs drives the demand for contract manufacturing services. The biopharmaceutical contract manufacturing market experienced double-digit growth over the past three years as new biopharmaceuticals reached the market or entered the pipeline. High demand plus low capacity expansion rates caused high industry utilization rates last year. In response, biopharmaceutical contract manufacturing organizations (CMOs) are aggressively adding capacity and investing in productivity improving technologies. 

    The information presented in this article draws from HighTech Business Decisions’ latest report, “Biopharmaceutical Contract Manufacturing 2017: Growing Markets, Capacities, and Innovations.” This report uses primary research from senior-level executives and scientists at pharmaceutical and biotechnology companies plus executives at contract manufacturing organizations. For purposes of our article, HighTech Business Decisions defines biopharmaceuticals as complex molecules created through the genetic manipulation of living cells or organisms used for therapeutics or vaccines. 

    Demand and utilization rates
    Over the past three years, the biopharmaceutical contract manufacturing market grew at a compound annual rate of 13%, higher than the previously projected growth rates of 8% to 10%. Both higher volumes and higher prices drove this growth. The growth in volumes occurred for both clinical and commercial products. Last year, the biopharmaceutical contract manufacturing markets reached $3.8 billion. This year, the biopharmaceutical contract manufacturing market will grow 8% and surpass $4 billion.

    During the first half of this decade, capacity utilization rates at most CMOs were below ideal levels. The industry had excess capacity. Capacity was readily available. With large fixed costs to cover, the CMOs experienced an intensely competitive marketplace causing downward price pressure and less favorable contract terms. Thus, most CMOs limited their capacity expansion plans. With low capacity investments, capacity increased at a slower rate than demand. This led to very high capacity utilization rates with little or no excess capacity available by 2016 (see Figure A). Furthermore, with the acceptance of single-use bioreactors, CMOs could economically add production capacity in smaller increments. As a result, contract mammalian cell culture capacity grew at a compound annual rate of 4% from 2011 through 2014. 

    Bookings
    To confirm higher utilization rates, we investigated CMOs booking levels in 2016. From our study, a large majority of the CMOs reported their capacity either fully or nearly-fully booked in 2016. Furthermore, the larger CMOs were more likely to be fully booked compared to smaller CMOs. In addition, mammalian cell culture production was more fully booked compared to microbial fermentation production. In response to high capacity utilization rates, pharmaceutical and biotechnology companies booked manufacturing slots in advance and locked in capacity for longer periods to ensure availability. On average, CMO facilities were booked 16 months into the future in 2016.

    Below are selected comments from CMOs regarding their production lead times:
    • “One plant is fully booked until the middle of 2018 and the other until the middle of 2017. The lead time is 9 to 16 months.” —CMO Respondent
    • “Booking manufacturing slots are always in flux. We have existing customers that have booked slots for the next two years and new projects that will take two years. Right now, we are booking into 2018.” —CMO Respondent
    • “I expect we’ll be fully booked for drug substance this year in the U.S. and into 2018 in Europe.”  —CMO Respondent
    • “Some of our products are booked out for several years. Clients could get a spot in about nine months.” —CMO Respondent
    • “Slots would be available for large-scale mammalian products in 2020, large-scale microbial products in 2018, small-scale mammalian products in 2018, and small-scale microbial products in 2018.” —CMO Respondent
    • “Our next opening is about nine months out. We have got capacity booked out for 18 months based on forecast predictions.” —CMO Respondent
    Higher prices
    The lack of excess capacity also affects prices paid for biopharmaceutical contract manufacturing services. Overall, 79% of the pharmaceutical and biotechnology executives in our study have observed higher prices for biopharmaceutical contract manufacturing services (Figure B). The lack of excess capacity is the main reason for the price increase. The pharmaceutical and biotechnology executives also observed that the lack of excess capacity is more prominent at the top-tier CMOs. This observation by the biopharmaceutical respondents is consistent with the analysis that 80% of the large contractors reported their manufacturing plants were fully booked in 2016. The respondents also saw higher prices for analytical testing, support activities, and raw materials. From the respondents’ inputs, prices have increased from 5% to 50%, with an average observed price increase of 18%. For the few respondents who saw stable prices, they attributed long-term supply agreements and strategic alliances, with set prices, as the reasons they have not experienced higher prices.

    Below are selected comments from our study’s respondents regarding their observation of biopharmaceutical contract manufacturing prices:
    • “We have been seeing a steady increase in the unit-per-effort pricing.  It’s a supply and demand situation. A few years ago, the CMOs were eager to develop a relationship early on to get you in the door and were willing to offer lower costs with the understanding that once they had built a relationship with you, they were more likely to get your business down the line.” —Pharma/Biotechnology Respondent
    • “It was easier to find capacity five years ago. Now there are so many mAbs in later stages that there’s a capacity crunch. We don’t get access to all the scales of production that we want. The base price for runs might be the same, but prices for support activities are increasing, e.g., regulatory, analytical. Nowadays, things are good for CMOs.” —Pharma/Biotechnology Respondent
    • “We are seeing higher prices from CMOs for biopharmaceutical services. There is some waning of capacity. Batch prices have gone up about 10%, and analytical testing about 5%.”—Pharma/Biotechnology Respondent
    • “For the gene therapy space, batch prices seem to be going up as the demand goes up. We are struggling to find CMOs for cell banking, process development, and analytical testing.” —Pharma/Biotechnology Respondent
    • “Many CMOs’ prices are very similar. There is not that much difference at 1,000 L to 2,000 L scale. The prices are 10% higher than five years ago.” —Pharma/Biotechnology Respondent
    • “Each time we go back to a CMO the prices are higher. Over the last three years, prices for manufacturing, purification, vialing and testing have all increased. The first manufacturing run we did one-and-a-half years ago costs $0.8 million, now it costs $1.2 million. That’s a 40% increase. Another area where with large increases is analytical development and validation; charges are up 30% to 40%. We are also seeing a 10% to 20% increase for analytical testing.” —Pharma/Biotechnology Respondent
    • “Prices are higher. Five years ago there was more capacity. We recently received a quote that was 50% higher than the one we’d had received previously, although to be fair, we haven’t negotiated it down yet.” —Pharma/Biotechnology Respondent
    CMOs add capacity
    In response to the high capacity utilization rates, CMOs are tightly managing schedules to meet critical production requirements. As indicated by the higher utilization rates, CMOs are also hiring more personnel and adding more shifts. Although not expanding overall industry capacity, CMO consolidations provide more financially sound and capable alternatives for some clients. In addition, smaller CMOs are working with each other as a network to meet their clients’ needs. Besides these and other short-term actions, CMOs are investing in new capacity. These investments include expanding existing facilities, building new sites, and installing single-use technologies for more flexible capacity. Consequently, mammalian cell culture capacity will grow at a compound annual rate of 12% from the period of 2014 through 2019—a rate greater than overall demand.

    From our study, three-quarters of the CMOs are adding new capacity over the next few years. The result from these additions will double total industry capacity this decade. For mammalian cell culture capacity, nearly one-fifth of the capacity increase will be single-use bioreactors. These capacity increases will support both clinical- and commercial-phase projects. The respondents also noted their adding or adding to other production-related capabilities including a) continuous manufacturing/perfusion, b) analytical capability, c) cell-line development, d) high-titer processes, and e) process development capability.

    Comments from CMO respondents regarding new capacity investments are shown below:
    • “We are in negotiation for a commercial project. We expect to increase capacity with two trains of 2,000 L which will enhance our capabilities and increase compliance.” —CMO Respondent
    • “Mostly, we are investing in more manufacturing capacity. We have a 5,000 L mammalian facility approved, and we are working on a 5,000 L microbial facility. It has not been approved yet. We are adding process characterization and cell development capability.” —CMO Respondent
    • “We’re mainly adding capacity (e.g., more incubators, more disposable bioreactors) to produce material for preclinical and Phase I. We will also be doing more process development for serum-free production.” —CMO Respondent
    • “We have invested in disposables for both up- and downstream processing. Also, more analytical capabilities, such as digital PCR and UPLC.” —CMO Respondent
    • “We will be adding microbial expression systems and looking for novel technology, such as disposable technology, that can be used to reduce overall time for first-to-patient.” —CMO Respondent
    • “We will continue to work on microbial technology and invest in soluble expression and in vitro refolding. Our biggest challenge right now is to increase capacity to satisfy increasing demands, since our customer base in late phase is growing.” —CMO Respondent
    • “We will continue investment in drug development and product development capability. We want to be able to offer our clients a broader range of services so we can build our pipeline of projects coming into the bioreactors. We want to have a pipeline of future partnerships with clients who will stay with us once we develop their process. We are considering investing in mammalian culture capability. Clients want cell culture.”—CMO Respondent
    • “In the future, we will invest in complex processes (also legacy), continuous manufacturing, high-titer processes and second generation processes.” —CMO Respondent
    • “Our current emphasis is on expanding our commercial capabilities. We are expanding manufacturing on the mammalian side supporting late-stage projects. Previously, we focused on early-stage only. We are looking at new perfusion technology with complementary downstream capacity. In the biosimilar space, some clients see perfusion manufacturing as the most effective way to exert a finer degree of control on the manufacturing process and to minimize the cost of goods. In fed-batch processes where the bioreactor is occupied for an extended period of time, molecules made early will sit in the growth media for longer and are more likely to undergo modifications that affect the character of the product. We are investing in 300 L single-use fermenters to provide additional smaller scale capacity, mostly for early-stage projects, although we are engaged on a couple of inquiries for the small-scale capacity for late-stage or commercial fermenter projects.” —CMO Respondent
    • “In the next five years, in addition to our upcoming expansions we will be investing in an in-line dilution system.” —CMO Respondent
    Closing
    Last year, capacity utilization rates were at very high levels. As a result, the industry has experienced more favorable pricing and contract terms. In response to the higher demand, CMOs are adding new capacity and investing in process improvements. From our analysis, we expect the market to continue to grow and exceed $4 billion in 2017. 


    William Downey is the president of HighTech Business Decisions, a market research and consulting company that has been publishing reports on the biopharmaceutical contract manufacturing market since 1997. For more information, visit www.hightechdecisions.com or call (408) 978-1035.
    Related Searches
    • Pharma
    • Preclinical
    • capacity
    • pipeline
    Suggested For You
    Vetio Animal Health Vetio Animal Health
    Boehringer Inaugurates Biopharma Mfg. Facility in China Boehringer Inaugurates Biopharma Mfg. Facility in China
    Trends in New Technologies & Budgets Trends in New Technologies & Budgets
    Heading to BIO 2017! Heading to BIO 2017!
    Dr. Reddy’s Expands Biomanufacturing Capabilities Dr. Reddy’s Expands Biomanufacturing Capabilities
    Volition Opens New R&D Facility in Belgium  Volition Opens New R&D Facility in Belgium
    Biopharma Fill Finish Contract Manufacturing Market Biopharma Fill Finish Contract Manufacturing Market
     Vantage Consulting is First Systems Integrator to Join PBOA Vantage Consulting is First Systems Integrator to Join PBOA
    Sharp Biotechnology Center of Excellence Sharp Biotechnology Center of Excellence
    Capsugel Expands Late-Stage Inhalation Development Capabilities Capsugel Expands Late-Stage Inhalation Development Capabilities
    Aptar Pharma Inaugurates Congers Site Expansion Aptar Pharma Inaugurates Congers Site Expansion
    How Can Contract Manufacturers Grow When Operational Performance Does Not Meet Expectations? How Can Contract Manufacturers Grow When Operational Performance Does Not Meet Expectations?
    QPSI Acquires International Labs QPSI Acquires International Labs
    Patheon Completes Acquisition of SC Mfg. Site Patheon Completes Acquisition of SC Mfg. Site
    Cytovance Names Senior VP of Mfg. Cytovance Names Senior VP of Mfg.

    Related Features

    • Biologics, Proteins, Vaccines | Biosimilars | Drug Development
      Biopharma Contract Manufacturing: Robust Growth Ahead

      Biopharma Contract Manufacturing: Robust Growth Ahead

      The biopharmaceutical contract manufacturing market is projected to reach $6.3 billion in 2020, and it will continue to grow over the next five years.
      William Downey, HighTech Business Decisions 11.17.20

    • Biologics, Proteins, Vaccines | Inspections | Supply Chain
      Inspecting the Unexpected

      Inspecting the Unexpected

      Preparing quality control processes for COVID-19 vaccine candidates.
      Dr. Andrea Sardella and Raffaele Pace, Stevanato Group 11.17.20

    • Biosimilars
      Biosimilar Manufacturing Strategies

      Biosimilar Manufacturing Strategies

      Five steps to competing in a post-patent expiry era.
      George I’ons, Owen Mumford Pharmaceutical Services 09.09.20


    • Biologics, Proteins, Vaccines | Drug Development | Regulatory Affairs
      Expediting a COVID-19 Vaccine: FDA Approval Process

      Expediting a COVID-19 Vaccine: FDA Approval Process

      The pressures of the pandemic are pushing sponsors and FDA to look at both efficacy and speed in developing a vaccine.
      Kristin Brooks, Managing Editor 09.09.20

    • Biologics, Proteins, Vaccines
      CAR-T Cell Therapy in Clinical Trials

      CAR-T Cell Therapy in Clinical Trials

      The importance of CAR-T cell therapy in clinical trials: the industry’s evolving, maturing focus
      Panteli Theocharous, Cell and Gene Therapy Strategy Lead, PPD 06.04.20

    • Biologics, Proteins, Vaccines
      Cell Therapy Manufacturing

      Cell Therapy Manufacturing

      Addressing the growing pains in cell therapy manufacturing
      Dr. Alessandra De Riva, Director of Process Development, Mogrify Ltd. 06.04.20


    • Biologics, Proteins, Vaccines
      The New Wave of Innovation

      The New Wave of Innovation

      Cell and gene therapies represent the new wave of innovation in the life sciences industry
      Tim Wright, Editor, Contract Pharma 06.04.20

    • Biosimilars
      The U.S. Biosimilars Market: Shaking the “Laggard” Label

      The U.S. Biosimilars Market: Shaking the “Laggard” Label

      Biosimilar uptake set to reshape the U.S. market
      Katya Svoboda and Bob Swann, ICON 05.05.20

    • Biologics, Proteins, Vaccines
      CEO Spotlight: Dr. Tae Han Kim

      CEO Spotlight: Dr. Tae Han Kim

      Samsung Biologics’ chief executive talks biopharma outsourcing trends, company growth initiatives and the impact of the coronavirus pandemic
      Tim Wright, Editor, Contract Pharma 05.05.20


    • Biologics, Proteins, Vaccines
      Covid 19: Impact on Bioprocessing and Outsourcing

      Covid 19: Impact on Bioprocessing and Outsourcing

      Outsourcing of biologics is increasing due to Covid-19, but what will change in the long-run?
      Ronald A. Rader & Eric S. Langer, BioPlan Associates 05.05.20

    • Biologics, Proteins, Vaccines
      The Evolution of the ADC Manufacturer

      The Evolution of the ADC Manufacturer

      How CMDOs can rise to the occasion
      Lisa McDermott and Jyothi Swamy, MilliporeSigma 04.01.20

    • Biologics, Proteins, Vaccines
      Biopharma Contract Manufacturing Pricing Analysis

      Biopharma Contract Manufacturing Pricing Analysis

      Expect increased prices over the next two years, but at slightly lower than historical trends
      William Downey, HighTech Business Decisions 01.28.20


    • Biologics, Proteins, Vaccines | Parenterals
      A Changing Healthcare Landscape

      A Changing Healthcare Landscape

      Navigating the road ahead with a focus towards patient centricity
      Peter Soelkner, Vetter Pharma International GmbH 01.28.20

    • Biologics, Proteins, Vaccines
      Regenerative Medicine: Overcoming the supply chain challenges

      Regenerative Medicine: Overcoming the supply chain challenges

      Accomplishing the goal of widespread use of regenerative medicine doesn’t come without its challenges.
      Rich Quelch, Global Head of Marketing, Origin 11.20.19

    • Biologics, Proteins, Vaccines
      Challenges and Opportunities in Vaccines Drug Development

      Challenges and Opportunities in Vaccines Drug Development

      As the uptake in vaccines continues to fall, the general public needs to be better informed.
      Adrian Wildfire, Scientific Director, SGS Life Sciences 11.20.19

    Trending
    • Lonza To Exit Pharma Softgels And Liquid-Filled Hard Capsules
    • The Future Of Clinical Trials Series: Part I
    • Grifols Begins COVID-19 Plasma Treatment Trial
    • Thermo Fisher Buys Novasep's Viral Vector Manufacturing Biz
    • NovaQuest Private Equity Acquires CoreRx
    Breaking News
    • WDSrx Expands Warehouse Network
    • Piramal Inks Clinical Supply Deal with Theratechnologies
    • Recipharm Signs Manufacturing Deal with Enzymatica
    • CDMO Northway Biotech Expands in U.S.
    • Global Biosciences Co. Selects ValGenesis VLMS
    View Breaking News >
    CURRENT ISSUE

    November/December 2020

    • Modeling Process Safety Workflows in Pharmaceutical Manufacturing Scale-Up
    • Ensuring Quality During the Transfer and Scale Up of Rx Drugs
    • Inspecting the Unexpected
    • Cold Chain Trends
    • Catering for the Complex
    • Biopharma Contract Manufacturing: Robust Growth Ahead
    • DCAT President Talks COVID-19, Drug Manufacturing and Innovation
    • The Single-Use Mixing Landscape: Evaluating Your Options
    • Self-Medication: Flexibility for Patients and Drug Manufacturers
    • Decentralized Trials Fuel AI Revolution in Clinical Research
    • View More >

    Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
    You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

    • About Us
    • Privacy Policy
    • Terms And Conditions
    • Contact Us

    follow us

    Subscribe
    Nutraceuticals World

    Latest Breaking News From Nutraceuticals World

    NIH Study Compares Low-Fat, Plant-based to Low-Carb, Animal-Based Diet
    Gadot Positions Mineral Line for Vegan Market
    Nutritfy India to Launch Global Broadcast Channel Covering Nutrition
    Coatings World

    Latest Breaking News From Coatings World

    IGL Coatings Launches Graphene Reinforced Dual System Ceramic Coating
    Miller Paint Declares Simple Serenity its 2021 Color of the Year
    TAUBMANS Paint by PPG Releases ‘Chromatic Joy’ Palettes
    Medical Product Outsourcing

    Latest Breaking News From Medical Product Outsourcing

    PPE Moves into New Manufacturing Facility
    Neurent Medical Closes $25 Million Series B Financing
    Alcon Releases PRECISION1 for Astigmatism Contact Lenses in U.S.
    Contract Pharma

    Latest Breaking News From Contract Pharma

    WDSrx Expands Warehouse Network
    Piramal Inks Clinical Supply Deal with Theratechnologies
    Recipharm Signs Manufacturing Deal with Enzymatica
    Beauty Packaging

    Latest Breaking News From Beauty Packaging

    Lageen Tubes Launches Mono-Material PE Tube Solutions
    Jason Jones Loses Battle with Covid-19
    Weleda Celebrates 100 Years By 'Opening' Its Gardens
    Happi

    Latest Breaking News From Happi

    Ipsy Adds New Personal Care Brand
    John Masters Organics Rolls Out Roll-On Fragrances
    Weleda Celebrates 100 Years of Beauty
    Ink World

    Latest Breaking News From Ink World

    Morancé Soudure France Adds Comexi F2 MC 10-color Flexo Press
    THIMM Group Installs 1st Koenig & Bauer CorruFLEX
    Cowan Graphics Adds Fujifilm Inca OnsetX3 HS
    Label & Narrow Web

    Latest Breaking News From Label & Narrow Web

    Lemu Group engineers mask-making machine
    Niagara Label upgrades with Nilpeter flexo press
    Soma partners with Moore & Moore in US
    Nonwovens Industry

    Latest Breaking News From Nonwovens Industry

    Lemu Group Engineers Mask-Making Machine
    Armbrust American Adds Meltblown Manufacturing
    P&G Reports 8% Sales Increase
    Orthopedic Design & Technology

    Latest Breaking News From Orthopedic Design & Technology

    Siemens Healthineers’ DR Systems Cleared by FDA
    Former Medtronic Exec Appointed Zimmer Biomet's Chief Transformation Officer
    SeaSpine Launches Regatta Lateral Plates
    Printed Electronics Now

    Latest Breaking News From Printed Electronics Now

    UDC Subsidiary Adesis' Website Wins 2020 MarCom Platinum Award
    Roadsimple Modernizes Warehouse Ops with Zebra Technologies
    Graphene Flagship Launches Redesigned Website

    Copyright © 2021 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

    AD BLOCKER DETECTED

    Our website is made possible by displaying online advertisements to our visitors.
    Please consider supporting us by disabling your ad blocker.


    FREE SUBSCRIPTION Already a subscriber? Login